文献速递中医内科中药与中成药合理使用

参麦注射液改善心力衰竭患者能量代谢的随机对照试验

Shenmai Injection Improves Energy Metabolism in Patients With Heart Failure: A Randomized Controlled Trial.
PubMed 文献 · Front Pharmacol · 2020-04-17

该单盲对照试验将120例心衰患者随机均分为参麦注射液组、曲美他嗪组和对照组,在标准治疗基础上干预7天。结果显示三组NYHA分级、中医证候积分和BNP均下降,但参麦组这些指标较曲美他嗪组和对照组显著升高(P<0.05);NYHA III-IV级参麦组患者能量代谢改善,表现为血清FFA、LA、PA和BCAA水平变化。结论认为参麦联合标准治疗与心功能改善相关,其获益可能与能量代谢改善有关,且似优于曲美他嗪。

要点

  • 参麦注射液联合标准治疗7天可改善心衰患者心功能相关指标。
  • 参麦组NYHA III-IV级患者能量代谢改善,优于曲美他嗪组和对照组。
  • 三组NYHA分级、中医证候积分和BNP均下降,但参麦组这些指标显著升高(P<0.05)。

核心结论

  • 参麦注射液联合心衰标准治疗与心功能改善相关,获益可能源于能量代谢改善。
  • 参麦注射液对心衰的获益似乎比曲美他嗪更显著。

研究设计与样本

  • 单盲、对照研究,随机将120例符合条件的心衰患者均分为三组。
  • 三组分别在标准心衰药物治疗基础上接受参麦注射液、曲美他嗪或对照干预,疗程7天。
  • 主要终点为血清游离脂肪酸、葡萄糖、乳酸、丙酮酸和支链氨基酸的变化。
  • 次要结局包括NYHA功能分级、中医证候积分、LVEF、LVIDd、LVIDs和BNP。

主要发现

  • 治疗1周后,三组NYHA功能分级、中医证候积分和BNP水平均逐渐下降。
  • 参麦组上述指标较曲美他嗪组和对照组显著升高(P<0.05)。
  • NYHA III-IV级参麦组患者能量代谢改善,表现为血清FFA、LA、PA和BCAA水平变化,优于曲美他嗪组和对照组。

临床怎么用

  • 对心衰患者可在标准治疗基础上考虑联合参麦注射液以改善心功能相关指标。
  • 对NYHA III-IV级心衰患者,参麦注射液可能有助于改善能量代谢。
  • 参麦注射液的获益可能不劣于甚至优于曲美他嗪,但需结合患者具体情况选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, the application of Shenmai (SM) injection, a traditional Chinese medicine (TCM), to treat heart failure (HF) has been gradually accepted in China. However, whether SM improves energy metabolism in patients with HF has not been determined due to the lack of high-quality studies. We aimed to investigate the influence of SM on energy metabolism in patients with HF. METHODS: This single-blind, controlled study randomly assigned 120 eligible patients equally into three groups receiving SM, trimetazidine (TMZ), or control in addition to standard medical treatment for HF for 7 days. The primary endpoints were changes in free fatty acids (FFAs), glucose, lactic acid (LA), pyroracemic acid (pyruvate, PA) and branched chain amino acids (BCAAs) in serum. The secondary outcomes included the New York Heart Association (NYHA) functional classification, TCM syndrome score (TCM-s), left ventricular injection fraction (LVEF), left ventricular internal diastolic diameter (LVIDd), left ventricular internal dimension systole (LVIDs), and B-type natriuretic peptide (BNP). RESULTS: After treatment for 1 week, the NYHA functional classification, TCM-s, and BNP level gradually decreased in the patients in all three groups, but these metrics were significantly increased in the patients in the SM group compared with those in the patients in the TMZ and control groups (P < 0.05). Moreover, energy metabolism was improved in the NYHA III-IV patients in the SM group compared with those in the patients in the TMZ and control groups as evidenced by changes in the serum levels of FFA, LA, PA, and BCAA. CONCLUSIONS: Integrative treatment with SM in addition to standard medical treatment for HF was associated with improved cardiac function compared to standard medical treatment alone. The benefit of SM in HF may be related to an improvement in energy metabolism, which seems to be more remarkable than that following treatment with TMZ.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang SM, Ye LF, Wang LH, et al. Shenmai Injection Improves Energy Metabolism in Patients With Heart Failure: A Randomized Controlled Trial. Front Pharmacol. 2020. PMID: 32362824. doi:10.3389/fphar.2020.00459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。